Oral verapamil effects on global and regional left ventricular diastolic filling in hypertrophic cardiomyopathy.
To assess the effects of oral verapamil therapy on global and regional left ventricular (LV) diastolic filling of hypertrophic cardiomyopathy (HCM), we studied 9 patients with HCM by radionuclide ventriculography and M-mode echocardiography before and after 2 weeks of oral verapamil therapy (240 mg/day). LV regional function was assessed by subdividing the LV region of interest into 4 regions from which global, septal, apical and lateral time-activity curves and their first-derivative curves were derived. Diastolic asynchrony during early diastole was measured as the sum of the absolute values (total delta t) of the time differences (delta t) from peak filling rate in the global left ventricle to that in each of the 3 regions. Verapamil did not alter LV systolic function globally and regionally. Global LV peak filling rate improved after verapamil therapy from 1.92 +/- 0.59 to 2.35 +/- 0.63 end-diastolic counts/s (p less than 0.02) without altering regional peak filling rates significantly. Global and regional times to peak filling rate showed a shortening or no change despite a tendency to increase in the diastolic time after verapamil therapy. The total delta t decreased from 93 +/- 61 to 41 +/- 23 ms after verapamil (p less than 0.05), indicating more synchronous LV diastolic filling after verapamil. There was a negative correlation between the global peak filling rate and the total delta t (r = -0.54, p less than 0.05, n = 18), suggesting that the global peak filling rate may improve after verapamil therapy in association with the decrease in the asynchronous LV diastolic filling.(ABSTRACT TRUNCATED AT 250 WORDS)
Yamagishi
T
T
Second Department of Internal Medicine, Yamaguchi University School of Medicine, Ube, Japan.
Ozaki
M
M
Kusukawa
R
R
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D002312:Cardiomyopathy, Hypertrophic / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000503:physiopathology*; D003971:Diastole / Q000187:drug effects*; D004452:Echocardiography; D005260:Female; D015637:Gated Blood-Pool Imaging; D006321:Heart / Q000000981:diagnostic imaging; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D016277:Ventricular Function, Left / Q000187:drug effects*; D014700:Verapamil / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
D014700:Verapamil